Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate NeoGenomics, Inc. before investing.

In this article, we go over a few key elements for understanding NeoGenomics, Inc.’s stock price such as:

• NeoGenomics, Inc.’s current stock price and volume
• Why NeoGenomics, Inc.’s stock price changed recently
• Upgrades and downgrades for NEO from analysts
• NEO’s stock price momentum as measured by its relative strength

About NeoGenomics, Inc. (NEO)

Before we jump into NeoGenomics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients’ oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

Want to learn more about NeoGenomics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about NeoGenomics, Inc..

NeoGenomics, Inc.’s Stock Price as of Market Close

As of January 16, 2026, 10:47 AM, CST, NeoGenomics, Inc.’s stock price was $12.640.

NeoGenomics, Inc. is down 1.48% from its previous closing price of $12.830.

During the last market session, NeoGenomics, Inc.’s stock traded between $12.545 and $13.000. Currently, there are approximately 128.42 million shares outstanding for NeoGenomics, Inc..

NeoGenomics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

NeoGenomics, Inc. Stock Price History

NeoGenomics, Inc.’s (NEO) price is currently up 7.48% so far this month.

During the month of January, NeoGenomics, Inc.’s stock price has reached a high of $13.740 and a low of $11.415.

Over the last year, NeoGenomics, Inc. has hit prices as high as $15.320 and as low as $4.720. Year to date, NeoGenomics, Inc.’s stock is up 7.48%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused NeoGenomics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of January 15, 2026, there was 1 analyst who downgraded NeoGenomics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate NeoGenomics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on NeoGenomics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

NeoGenomics, Inc.’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about NeoGenomics, Inc. (NEO) by visiting AAII Stock Evaluator.

Relative Price Strength of NeoGenomics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of January 15, 2026, NeoGenomics, Inc. has a weighted four-quarter relative price strength of 4.56%, which translates to a Momentum Score of 67 and is considered to be Strong.

Want to learn more about how NeoGenomics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

NeoGenomics, Inc. Stock Price: Bottom Line

As of January 16, 2026, NeoGenomics, Inc.’s stock price is $12.640, which is down 1.48% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like NeoGenomics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.